PDS Biotechnology Corporation $PDSB Shares Bought by Tempus Wealth Planning LLC

Tempus Wealth Planning LLC raised its stake in PDS Biotechnology Corporation (NASDAQ:PDSB) by 154.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 47,800 shares of the company’s stock after buying an additional 29,000 shares during the period. Tempus Wealth Planning LLC’s holdings in PDS Biotechnology were worth $64,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of PDSB. Jane Street Group LLC acquired a new stake in shares of PDS Biotechnology in the 4th quarter worth approximately $58,000. Two Sigma Investments LP boosted its position in PDS Biotechnology by 273.5% during the fourth quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock worth $107,000 after purchasing an additional 48,132 shares in the last quarter. Iron Gate Global Advisors LLC acquired a new stake in PDS Biotechnology in the first quarter valued at $89,000. Blair William & Co. IL increased its position in shares of PDS Biotechnology by 63.3% in the first quarter. Blair William & Co. IL now owns 257,200 shares of the company’s stock valued at $306,000 after buying an additional 99,700 shares in the last quarter. Finally, Armistice Capital LLC acquired a new position in shares of PDS Biotechnology during the 1st quarter worth $5,259,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Trading Down 1.0%

Shares of PDSB stock opened at $1.02 on Monday. The company has a market capitalization of $47.97 million, a price-to-earnings ratio of -1.11 and a beta of 1.15. The company has a current ratio of 2.92, a quick ratio of 2.92 and a debt-to-equity ratio of 0.81. The firm has a 50-day moving average price of $1.17 and a 200 day moving average price of $1.27. PDS Biotechnology Corporation has a twelve month low of $0.85 and a twelve month high of $4.29.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03. Research analysts forecast that PDS Biotechnology Corporation will post -1.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on PDSB shares. HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of PDS Biotechnology in a research note on Tuesday, July 1st. Wall Street Zen lowered shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, June 14th. Two analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $10.00.

PDS Biotechnology Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.